Benralizumab in severe eosinophilic asthma: a comprehensive systematic review and meta-analysis of randomized controlled trials evaluating lung function, asthma control, and safety outcomes Authors: Abbas Al Mutair, Yasmine Alabbasi, Hanan F. Alharbi, Hanan Alyami, Haifa Mohmmed Al-Shammari, Abdullah Awad Al-Omari, Eman A. Bomozah, Faiza Aljarameez, Muhammad Daniyal Published: 2026 ABSTRACT BackgroundBenralizumab, a monoclonal antibody, targets eosinophils by blocking an interleukin-5 receptor, improving severe allergic asthma. Severe eosinophilic asthma affects about 10% of asthma patients and often requires high-dose corticosteroids, which are linked to adrenal insufficiency and poor outcomes. This study will perform a detailed review and meta-analysis to evaluate the effectiveness and safety of benralizumab in eosinophilic asthma.MethodThe analysis included relevant RCTs identified through systematic searches of PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) from April 2013 to January 2024. The study included variables such as exacerbation, Asthma Control Questionnaire (ACQ), forced expiratory volume (FEV₁), and adverse events.ResultsA total of 5502 patients with eosinophilic asthma were enrolled across 15 randomized-controlled trials; 3061 received benralizumab and 2441 received placebo. A meta-analysis showed that benralizumab significantly improved FEV₁ compared with control, with a pooled mean difference of 0.107 L (95% CI 0.059, 0.155; p < 0.001). Using a random-effects model with Hartung-Knapp adjustment, the pooled mean difference was − 0.174 (95% CI − 0.326, − 0.022; p = 0.030), indicating a statistically significant improvement in ACQ while the pooled odds ratio (OR) for adverse effects was 0.93 (95% CI 0.71, 1.23; p = 0.583) showing no statistically significant difference between benralizumab and control in the risk of adverse effects.ConclusionThe meta-analysis indicated that benralizumab provides significant improvement in lung function (FEV₁) and asthma control (ACQ) compared to placebo in severe eosinophilic asthma. Clinically, the average FEV₁ improvement of approximately 0.11 L represents a small but valuable gain for patients with significant baseline obstruction, though it falls below the threshold for a minimal clinically important difference (MCID) in ACQ scores. However, substantial heterogeneity was observed across studies, demonstrating that these pooled estimates represent average effects and that individual patient responses may vary considerably.Systematic review registrationPROSPERO CRD42024548225. Introduction Over 315 million people worldwide have asthma, and 10% of cases are severe or uncontrolled [1, 2]. Long-acting β2-agonists and high-dose inhaled corticosteroids are commonly used to treat severe or uncontrolled asthma [3]. However, most patients remain uncontrolled and face a substantial disease burden, including frequent exacerbations and hospitalizations [4]. Therefore, innovative medications with new mechanisms of action are needed to address this unmet medical need. One strategy targets eosinophilic inflammation, present in about 50% of asthma patients and associated with disease severity [5], leading to more frequent exacerbations and decreased lung function [6, 7]. Approximately 20–60% of individuals with severe asthma regularly use oral corticosteroids, which can cause adverse effects such as depression, diabetes, and cardiovascular disease [8, 9]. Notably, exposure to exogenous corticosteroids can suppress the hypothalamic–pituitary–adrenal axis, potentially resulting in adrenal insufficiency, a common yet under-evaluated side effect [10, 11]. This weakened stress response can lower resistance to infections and other illnesses [12]. Serious adverse events, including adrenal insufficiency, may occur after the equivalent of two to four sessions (cumulative exposure of 0.5–1.0 g) of oral corticosteroids [13], with risks increasing with prolonged therapy, frequent courses, or higher cumulative doses [14, 15]. Adrenal insufficiency, often called an adrenal crisis, can be fatal if untreated, especially during stress or concurrent illnesses [16, 17]. Biologics targeting specific immune pathways involved in asthma development have been shown to reduce exacerbation frequency, improve lung function and symptom control, and decrease reliance on oral corticosteroids in severe asthma [18, 19]. Benralizumab, a cytolytic monoclonal antibody targeting the α subunit of the interleukin-5 (IL-5) receptor, rapidly and nearly completely depletes eosinophils via increased antibody-dependent cell-mediated cytotoxicity [20]. Repeated administration in patients with mild to severe asthma significantly lowered eosinophil counts in sputum and airway walls [21]. For severe eosinophilic asthma, benralizumab notably reduced oral corticosteroid doses, improved lung function, and decreased exacerbations, with benefits lasting up to 2 years [22–24]. Pooled post-hoc analyses suggested that patients with elevated blood eosinophil counts (BEC), more frequent exacerbations, poor lung function, oral corticosteroid use, adult asthma diagnosis, and nasal polyposis experience greater therapeutic benefits [25–27]. Recent network and comparative meta-analyses (2022–2024) further contextualized the efficacy of IL-5 pathway biologics. A 2023 network meta-analysis concluded that benralizumab, mepolizumab, and reslizumab all significantly reduce annualized exacerbation rates compared to placebo in severe eosinophilic asthma [28]. Another study compared the IL-5-targeting therapies mepolizumab and benralizumab in EGPA, examining their mechanisms, effects on eosinophil suppression, and clinical efficacy to guide optimized treatment strategies and drug selection [29]. Benralizumab has reported benefits across multiple endpoints, including oral corticosteroid (OCS) dose reduction and asthma-specific quality of life (AQLQ); the present analysis intentionally focuses on lung function (FEV₁), symptom control (ACQ), exacerbation rates, and adverse events. Although OCS-sparing is a critical benefit of biologic therapy, it is typically evaluated in specific trial populations (e.g., ZONDA, SHAMAL) and is less consistently reported across the broader universe of randomized controlled trials. Similarly, quality-of-life instruments, while valuable, exhibit greater variability in measurement and reporting. Thus, this meta-analysis provides a focused synthesis of the most universally available endpoints to assess the efficacy and safety profile of benralizumab. Materials and methods The Cochrane Handbook of Systematic Reviews of Interventions was followed during this investigation [30]. The systematic review and meta-analysis were conducted in accordance with the PRISMA statement [31]. This study was registered with PROSPERO (CRD42024548225). Search strategy A comprehensive electronic search of PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) was conducted to identify all relevant randomized controlled trials published from April 2013 to January 2024. In PubMed, the search strategy was as follows: “benralizumab” OR “anti-IL-5 receptor” OR “MEDI-563”; “asthma” OR “asthmatic”; “eosinophilic” OR “eosinophil” OR “eosinophilia.” These three sets were combined using AND and further limited to randomized controlled trials using terms such as “randomized,” “randomised,” “placebo,” and publication types. The final search applied the English language and publication date limits from April 2013 to January 2024. Equivalent strategies were applied in Web of Science and Scopus. This procedure was performed by the two authors. Both authors performed systematic and independent searches of PubMed (including MEDLINE), EMBASE, and CENTRAL. Additional searches of Web of Science and Scopus were conducted to ensure comprehensiveness, but records from these sources were cross-checked against the primary databases to identify duplicates. Inter-rater reliability was calculated using Cohen’s κ. Rayyan Software received the results of electronic-database searches for screening and selection. Inclusion criteria Studies were included based on specific eligibility criteria to ensure methodological consistency and relevance. Only RCTs were considered, and the study population consisted of patients diagnosed with eosinophilic asthma. The intervention of interest was the use of benralizumab as part of the treatment. Additionally, studies were included to evaluate the effectiveness or impact of benralizumab in managing eosinophilic asthma. The inclusion of both adult and adolescent populations (≥ 12 years) was deliberate. The pathophysiology of severe eosinophilic asthma, driven by IL-5-mediated eosinophilic inflammation, is consistent across these age groups, and benralizumab’s mechanism of action targets this pathway irrespective of age. Furthermore, its clinical approval and use extend to adolescents. Including studies such as Busse et al. (2021) allows for a more comprehensive safety and efficacy profile that reflects real-world application. The selection of FEV₁, ACQ, exacerbation rates, and adverse events as primary outcomes was based on their consistent reporting across all eligible RCTs, ensuring methodological uniformity and maximizing the robustness of the pooled estimates. Outcomes such as OCS dose reduction and AQLQ scores, while clinically important, were reported in fewer studies or used heterogeneous definitions, precluding a reliable meta-analysis. Exclusion criteria Studies were excluded if they did not meet the predefined methodological and clinical criteria. Any study design other than RCTs, such as non-RCTs, case-control studies, cohort studies, reviews, or cross-sectional designs, was omitted. Research that did not involve patients diagnosed with eosinophilic asthma or did not assess benralizumab as part of the intervention was also excluded. In addition, studies were removed if they did not examine the effectiveness of benralizumab in the treatment of eosinophilic asthma. Data extraction Data extraction was performed independently by two authors using standardized forms. Using a pre-designed, standardized extraction form in Microsoft Excel, they separately retrieved data from the studies’ texts, tables, and figures. They extracted country, sample size, age, and gender for the summary and baseline data. The authors verified the accuracy of data extraction and resolved any issues through discussion. They also extracted data on exacerbation, adverse events, the ACQ, and FEV₁ as outcome variables. For agreement, inter-rater reliability was calculated using Cohen’s κ, demonstrating substantial agreement (κ = 0.88, 95% CI 0.82, 0.94). For full-text assessment, independent review yielded almost perfect agreement (κ = 0.92, 95% CI 0.87, 0.97). For FEV₁, we extracted the reported effect estimates as provided by each trial. The majority of included studies reported FEV₁ as least-squares mean (LSM) change from baseline to the end of the treatment period, derived from MMRM analyses. Where studies reported end-of-treatment values rather than change from baseline, we prioritized change-from-baseline data if available in the publication or supplementary materials. In all cases, we ensured that the extracted values represented the same metric (change from baseline) across studies to maintain consistency. All FEV₁ values were extracted in liters, the native unit of measurement, which allowed for the use of MD as the pooled effect measure. We selected MD over SMD because all studies measured FEV₁ using the same clinically standardized unit (liters), making MD directly interpretable and clinically meaningful. Quality assessment using the RoB-2.0 tool The authors independently conducted a risk-of-bias assessment, evaluating factors such as random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other potential sources of bias. The Cochrane risk-of-bias tool (RoB-2.0) [32] for RCTs, which consists of five domains (randomization, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result), was used to assess the risk of bias among RCTs. Data analysis To evaluate the differences between the continuous variables of the two treatments, the study employed a pooled mean difference (MD) with 95% CI, as all continuous outcomes (FEV₁ in liters, ACQ score) were measured on consistent, clinically standardized scales across trials. For all dichotomous outcomes, pooled odds ratios (ORs) with 95% CIs were used. Heterogeneity among studies was assessed using the χ2 test and the I2 statistic, with a χ2 value < 0.1 and an I2 value ≥ 50% indicating significant heterogeneity. The I2 statistic quantified the proportion of total variability across trials that is attributable to between-study heterogeneity rather than sampling error. If I2 was below 50%, a fixed-effect model was applied; otherwise, a random-effects model was used. Additionally, a post-hoc sensitivity analysis was performed by switching from a random effect to a fixed-effect model. The primary outcomes of interest were to assess the effectiveness of benralizumab for exacerbation, the ACQ, and FEV₁. Secondary outcomes included adverse events in patients who were treated with benralizumab. Statistical analysis was performed by Review Manager (RevMan) software version 5.3 [33]. The descriptive and graphical analyses were performed using R Studio. The effects were determined by combining the zz-value, with pp < 0.05 considered statistically significant. Description of adverse events Adverse effects are any negative medical events that occur following the administration of a therapeutic dose of a drug, which are not related to the intended treatment purpose. These events can either be caused by the drug or occur independently of it. Ethics The analyses of the study were performed using the previous studies, so no ethical approval is required for the systematic review and meta-analysis. No individual patient-level data were accessed or analyzed in this study. Results The database search yielded 477 articles; 189 were duplicates and were removed. Title and abstract screening were conducted on 288 articles. A total of 20 articles were included for full-text screening, and 15 RCTs [22–27, 34–46] were included in the meta-analysis (Fig. 1).Fig. 1PRISMA flowchart of the database searching and screening process PRISMA flowchart of the database searching and screening process Characteristics of the included studies A total of 5502 patients with eosinophilic asthma were enrolled across 15 randomized controlled trials, of whom 3061 received benralizumab, and 2441 received placebo. The included studies were conducted across a wide geographical range, including North America, Europe, and Asia, with substantial variability in sample size and demographic characteristics. Sample sizes ranged from small cohorts, such as Laviolette et al. in Canada [37] (17 benralizumab vs. 10 placebo), to large multinational trials such as SIROCCO [22] and CALIMA [35], each enrolling more than 800 participants. Mean participant age was generally consistent across studies, predominantly in the late 40 s to early 50 s, although one adolescent study conducted in Sweden [46] reported a substantially younger population (mean age approximately 15 years). Males comprised approximately 35–45% of participants in most studies, with balanced distribution across treatment arms, though higher proportions were observed in some European cohorts, such as Korn et al. in Germany [44]. Studies conducted in Japan and East Asia [38, 39] demonstrated comparable baseline age and sex distributions between the benralizumab and placebo groups, supporting internal validity. Similarly, U.S.-based trials [32, 34, and 38] reported closely matched demographic profiles across treatment arms. Additional trials highlighted geographic differences in baseline characteristics. In the USA, Castro et al. [41] enrolled 81 patients receiving benralizumab and 80 receiving placebo, with mean ages of 46.6 ± 13.2 and 45.6 ± 11.7 years, respectively; males represented 59.3% (n = 48) of the benralizumab group and 66.3% (n = 53) of the control group. In Italy, Canonica et al. [42] reported on 96 benralizumab-treated patients and 57 controls, with similar mean ages (53.1 ± 12.3 vs. 52.6 ± 11.1 years) and male proportions of 55.2% (n = 53) and 42.1% (n = 24), respectively. In the UK, the ANDHI trial [43] included 427 participants in the benralizumab arm and 229 in the placebo arm, with comparable mean ages of 52.5 ± 12.7 and 53.3 ± 12.5 years; males accounted for 38.4% (n = 164) and 40.6% (n = 93) of participants, respectively. Similarly, the BORA study conducted in the USA [27] enrolled 512 patients receiving benralizumab and 281 controls, reporting mean ages of 49.3 ± 14.8 and 48.2 ± 16.8 years, with male representation of 40.0% (n = 205) in the benralizumab group and 42.0% (n = 118) in the placebo group. In Germany, Korn et al. [44] studied 159 benralizumab-treated patients and 67 placebo recipients, with mean ages of 50.8 ± 11.4 and 52.2 ± 12.2 years; males comprised 61.0% (n = 97) and 70.1% (n = 47) of the two groups, respectively. Lastly, the UK-based SHAMAL trial [45] enrolled 125 patients in the benralizumab group and 43 in the control group, with mean ages of 58.1 ± 12.44 and 56.5 ± 11.7 years; male proportions were 44.8% (n = 56) and 53.5% (n = 23), respectively (Table 1, Fig. 2). Table 1Baseline characteristics of the included studiesStudy IDCountrySample size (drug)Sample size (control)Age, years (drug), mean (SD)Age, years (control), mean (SD)Male, n (%) DrugMale, n (%) ControlBleecker et al. 2016 (SIROCCO) [22]Multinational42544048.9 (13.2)49.6 (13.4)169 (39.8%)180 (40.9%)Busse et al. 2019 (BORA) [27]USA51228149.3 (14.8)48.2 (16.8)205 (40.0%)118 (42.0%)Busse et al. 2021 (Adolescents) [46]Sweden322915.5 (1.92)15.0 (1.7)13 (40.6%)12 (41.4%)Canonica et al. 2022 [42]Italy965753.1 (12.3)52.6 (11.1)53 (55.2%)24 (42.1%)Castro et al. 2014 [41]USA818046.6 (13.2)45.6 (11.7)48 (59.3%)53 (66.3%)Chipps et al. 2018 [40]USA25627147.3 (14.2)48.5 (13.7)94 (36.7%)100 (36.9%)Ferguson et al. 2017 (BISE) [36]USA10610548.3 (14.4)51.1 (12.6)44 (41.5%)38 (36.2%)FitzGerald et al. 2016 (CALIMA) [35]Multinational44144049.0 (14.3)48.8 (15.1)168 (38.1%)176 (40.0%)Harrison et al. 2021 (ANDHI) [43]UK42722952.5 (12.7)53.3 (12.5)164 (38.4%)93 (40.6%)Jackson et al. 2024 (SHAMAL) [45]UK1254358.1 (12.44)56.5 (11.7)56 (44.8%)23 (53.5%)Korn et al. 2021 [44]Germany1596750.8 (11.4)52.2 (12.2)97 (61.0%)47 (70.1%)Laviolette et al. 2013 [37]Canada171038.9 (13.8)40.2 (14.5)7 (41.2%)4 (40.0%)Ohta et al. 2018 [39]Japan23924851.0 (NR)50.0 (NR)103 (43.1%)101 (40.7%)Panettieri et al. 2020 (SOLANA) [34]USA11811551.9 (13.62)50.9 (12.34)44 (37.3%)32 (27.8%)Park et al. 2016 [38]Japan/South Korea262651.4 (13.8)50.8 (11.8)9 (34.6%)10 (38.5%)Total30612441Fig. 2Gender distribution of patients: benralizumab vs placebo group Table 1Baseline characteristics of the included studiesStudy IDCountrySample size (drug)Sample size (control)Age, years (drug), mean (SD)Age, years (control), mean (SD)Male, n (%) DrugMale, n (%) ControlBleecker et al. 2016 (SIROCCO) [22]Multinational42544048.9 (13.2)49.6 (13.4)169 (39.8%)180 (40.9%)Busse et al. 2019 (BORA) [27]USA51228149.3 (14.8)48.2 (16.8)205 (40.0%)118 (42.0%)Busse et al. 2021 (Adolescents) [46]Sweden322915.5 (1.92)15.0 (1.7)13 (40.6%)12 (41.4%)Canonica et al. 2022 [42]Italy965753.1 (12.3)52.6 (11.1)53 (55.2%)24 (42.1%)Castro et al. 2014 [41]USA818046.6 (13.2)45.6 (11.7)48 (59.3%)53 (66.3%)Chipps et al. 2018 [40]USA25627147.3 (14.2)48.5 (13.7)94 (36.7%)100 (36.9%)Ferguson et al. 2017 (BISE) [36]USA10610548.3 (14.4)51.1 (12.6)44 (41.5%)38 (36.2%)FitzGerald et al. 2016 (CALIMA) [35]Multinational44144049.0 (14.3)48.8 (15.1)168 (38.1%)176 (40.0%)Harrison et al. 2021 (ANDHI) [43]UK42722952.5 (12.7)53.3 (12.5)164 (38.4%)93 (40.6%)Jackson et al. 2024 (SHAMAL) [45]UK1254358.1 (12.44)56.5 (11.7)56 (44.8%)23 (53.5%)Korn et al. 2021 [44]Germany1596750.8 (11.4)52.2 (12.2)97 (61.0%)47 (70.1%)Laviolette et al. 2013 [37]Canada171038.9 (13.8)40.2 (14.5)7 (41.2%)4 (40.0%)Ohta et al. 2018 [39]Japan23924851.0 (NR)50.0 (NR)103 (43.1%)101 (40.7%)Panettieri et al. 2020 (SOLANA) [34]USA11811551.9 (13.62)50.9 (12.34)44 (37.3%)32 (27.8%)Park et al. 2016 [38]Japan/South Korea262651.4 (13.8)50.8 (11.8)9 (34.6%)10 (38.5%)Total30612441 Baseline characteristics of the included studies Gender distribution of patients: benralizumab vs placebo group Quality assessment of included studies by ROB2 All the trials included were randomized, categorizing them as having a low risk of selection bias. Studies were evaluated across five domains (D1 to D5), with judgments of high, some concerns, or low risk of bias. Among the included RCTs assessed by RoB 2.0, there was a low risk of bias = 10 studies, 2 high-risk studies = 2, and some concerns = 2 studies. Studies like [27, 34, 39, 43–46] have multiple “ + ” symbols across domains, indicating a thorough evaluation and likely a Low risk of bias. These studies are considered methodologically strong, with minimal concerns about bias affecting their results. All RCT studies included were classified as having a low risk of reporting bias. The results of each risk-of-bias item for the included studies are shown in Fig. 3.Fig. 3Risk-of-bias assessment of randomized controlled trials using the RoB-2.0 tool Risk-of-bias assessment of randomized controlled trials using the RoB-2.0 tool Comparison between benralizumab and control regarding FEV₁ A meta-analysis of 11 studies including 4553 participants (2503 receiving benralizumab, 2050 controls) showed that benralizumab provided statistically significant improved FEV₁ (in liters) compared with control, with a pooled mean difference of 0.107 L (95% CI 0.059, 0.155; p < 0.001). Individual study effect estimates varied, with most studies showing positive improvements. Substantial heterogeneity was observed (I2 = 71.2%, Q = 34.69, p < 0.001), likely reflecting differences in patient populations, study duration, and baseline lung function, justifying the use of a random-effects model. Between-study variance was low-to-moderate (τ2 = 0.0037, τ = 0.0605 L) (Fig. 4).Fig. 4Comparison between benralizumab and control regarding FEV₁ Comparison between benralizumab and control regarding FEV₁ Assessment of publication bias using Egger’s test revealed no significant asymmetry (t = − 0.69, p = 0.504), indicating minimal risk of small-study effects. These findings demonstrated that benralizumab provides a statistically significant improvement in lung function in patients with severe eosinophilic asthma. To further clarify it, a 0.107-L improvement represents approximately 3–5% of the predicted FEV₁ value for an average adult patient in these trials, whose baseline lung function was often below 60% of predicted (Fig. 5).Fig. 5Funnel plot of benralizumab and control regarding FEV₁ Funnel plot of benralizumab and control regarding FEV₁ Comparison between benralizumab and control regarding ACQ The meta-analysis included nine studies with a total of 3986 participants (2214 in the benralizumab group and 1772 in the control group) comparing benralizumab versus control for improvement in ACQ (scores). Individual study MD has a range from − 0.36 to 0.26, with most studies favoring benralizumab. (Fig. 6).Fig. 6Comparison between benralizumab and control regarding ACQ Comparison between benralizumab and control regarding ACQ Using a random-effects model with Hartung-Knapp adjustment, the pooled mean difference was − 0.174 (95% CI − 0.326 to − 0.022; p = 0.029), providing a statistically significant improvement in ACQ with benralizumab compared to control. It is important to note that this improvement is below the established minimal clinically important difference (MCID) of 0.5 points for the ACQ (scores), indicating that the average patient-reported benefit, while real, may be subtle. Heterogeneity across studies was substantial, with Cochran’s Q = 27.43 (df = 8, p < 0.001) and I2 = 70.8% (95% CI 42.2%, 85.3%) meaning that approximately 71% of the observed variability across studies is due to between-study heterogeneity (e.g., differences in patient populations, study design, or treatment protocols) rather than sampling error. The analysis accounted for between-study heterogeneity (multiplicative residual variance, tau2 = 3.8747) and used IVW (inverse variance weighting) by following Egger’s method. Findings from this meta-analysis suggest no significant publication bias based on Egger’s test (Fig. 7).Fig. 7Funnel plot of the studies comparing benralizumab and control ACQ outcomes Funnel plot of the studies comparing benralizumab and control ACQ outcomes Comparison between benralizumab and control regarding adverse events The meta-analysis comparing adverse effects between benralizumab and control participants included a total of 3871 participants (2,256 in the benralizumab group and 1615 in the control group) with 2549 events. Using a random-effects model, the pooled OR for adverse effects was 0.93 (95% CI 0.71, 1.23; p = 0.581). Heterogeneity across studies was moderate, with Cochran’s Q = 18.38, p = 0.048, between-study variance tau2 = 0.0643, and an I2 of 45.6%, suggesting that just under half of the observed variability reflects true differences between study effects (Fig. 8).Fig. 8Comparison between benralizumab and control regarding adverse events Comparison between benralizumab and control regarding adverse events Publication bias was assessed using a linear regression test of funnel plot asymmetry (Egger’s test). The test yielded t = − 1.73, df = 9, p = 0.1171, with a bias estimate of − 1.3921 (SE = 0.8033), having statistically significant evidence of small-study effects or publication bias. The test details also show a multiplicative residual heterogeneity variance of tau2 = 1.5309, with SE as the predictor and inverse variance as the weight. Some studies favored benralizumab (e.g., Canonica 2022, OR = 0.44 [0.22, 0.90]), while others favored control or showed no difference (e.g., Busse 2019, OR = 1.28 [0.94, 1.75]). The analysis suggested that benralizumab does not significantly increase or decrease the risk of adverse effects with moderate heterogeneity and no strong evidence of publication bias (Fig. 9).Fig. 9Funnel plot of the studies comparing benralizumab and control regarding AEs Funnel plot of the studies comparing benralizumab and control regarding AEs Comparison between benralizumab and control regarding exacerbation The random-effects meta-analysis of six studies comparing benralizumab with control for exacerbations included a total of 3007 participants (1598 in the benralizumab group and 1409 in the control group). The pooled MD favored benralizumab, with a statistically significant reduction in exacerbations of − 0.298 (95% CI − 0.511, − 0.085, p = 0.015). Individual study effect estimates ranged from − 0.51 in FitzGerald 2016 to − 0.04 in Panettieri 2020, with most studies showing a benefit of benralizumab over control (Fig. 10).Fig. 10Comparison between benralizumab and control regarding exacerbations Comparison between benralizumab and control regarding exacerbations Assessment of publication bias using Egger’s linear regression test of funnel plot asymmetry showed no evidence of significant small-study effects (t = − 0.75, p = 0.496), with a bias estimate of − 4.1268 (SE = 5.5214). The funnel plot analysis further supported the absence of asymmetry, suggesting that the pooled estimate is unlikely to be substantially influenced by publication bias. The analysis showed that benralizumab is associated with a statistically significant reduction in exacerbation rates compared with control. Heterogeneity across studies was moderate, with a Cochran’s Q of 13.03 (df = 5, p = 0.023), an I2 of 61.6% (95% CI 6.4%, 84.3%), indicating that a considerable proportion (approximately 62%) of the variability in exacerbation reduction estimates is due to between-study differences and a between-study variance tau2 of 0.0248. The Hartung-Knapp adjustment was applied to account for small-study effects in the random-effects model (Fig. 11).Fig. 11Funnel plot of the studies comparing benralizumab and control regarding exacerbations Funnel plot of the studies comparing benralizumab and control regarding exacerbations Sensitivity analysis The robustness of the findings was assessed using a leave-one-out sensitivity analysis for the key outcomes of FEV₁ (in liters) and ACQ (scores). For FEV₁, the pooled MD ranged from 0.095 L (95% CI 0.044, 0.146) to 0.118 L (95% CI 0.067, 0.169) across iterations of study’s removal. No single study’s removal altered statistical significance, indicating that the improvement in lung function attributed to benralizumab is robust. For the ACQ score, the pooled MD ranged from − 0.150 (95% CI − 0.310, 0.010) to − 0.195 (95% CI − 0.350, − 0.040). The consistency of these results across all iterations indicates that the observed heterogeneity (I2 = 71.2% for FEV₁; I2 = 70.8% for ACQ) stems from widespread clinical and methodological diversity across the included trials (e.g., baseline characteristics, dosing regimens, follow-up duration) rather than an outlier effect. This supports the interpretation that, despite variability in the magnitude of benefit across studies, the treatment effect of benralizumab is robust and not dependent on any single trial. The GRADE summary indicates that benralizumab provides clinically meaningful benefits over placebo in patients with severe eosinophilic asthma, particularly in improving lung function, asthma control, and reducing exacerbation frequency (Table 2). Table 2Summary of findings (GRADE): benralizumab vs placebo in severe eosinophilicOutcomeNo. of participants (studies)Relative effect (95% CI)Absolute effectsCertainty of evidence (GRADE)FEV₁ (L)4553 (11 rcts)MD 0.107 L (0.059, 0.155)Compared with placebo, benralizumab increased FEV₁ by a mean of 0.107 L⬤⬤⬤◯ ModerateᵃACQ score3986 (9 rcts)MD − 0.174(− 0.326, − 0.022)Compared with placebo, benralizumab reduced the ACQ score by approximately 0.17–0.21 points⬤⬤⬤◯ ModerateᵇExacerbation rate3007 (6 rcts)MD − 0.298(− 0.511, − 0.086)Compared with placebo, benralizumab resulted in 0.30 fewer exacerbations⬤⬤⬤◯ ModerateᶜAdverse events3871 (multiple rcts)OR 0.93 (0.71 to 1.23)No clinically meaningful difference in adverse events between groups⬤⬤⬤⬤ HighaDowngraded for inconsistency across trialsᵇDowngraded for imprecision of effect estimatesᶜDowngraded for heterogeneity among included studies Table 2Summary of findings (GRADE): benralizumab vs placebo in severe eosinophilicOutcomeNo. of participants (studies)Relative effect (95% CI)Absolute effectsCertainty of evidence (GRADE)FEV₁ (L)4553 (11 rcts)MD 0.107 L (0.059, 0.155)Compared with placebo, benralizumab increased FEV₁ by a mean of 0.107 L⬤⬤⬤◯ ModerateᵃACQ score3986 (9 rcts)MD − 0.174(− 0.326, − 0.022)Compared with placebo, benralizumab reduced the ACQ score by approximately 0.17–0.21 points⬤⬤⬤◯ ModerateᵇExacerbation rate3007 (6 rcts)MD − 0.298(− 0.511, − 0.086)Compared with placebo, benralizumab resulted in 0.30 fewer exacerbations⬤⬤⬤◯ ModerateᶜAdverse events3871 (multiple rcts)OR 0.93 (0.71 to 1.23)No clinically meaningful difference in adverse events between groups⬤⬤⬤⬤ HighaDowngraded for inconsistency across trialsᵇDowngraded for imprecision of effect estimatesᶜDowngraded for heterogeneity among included studies Summary of findings (GRADE): benralizumab vs placebo in severe eosinophilic MD − 0.174 (− 0.326, − 0.022) MD − 0.298 (− 0.511, − 0.086) aDowngraded for inconsistency across trials ᵇDowngraded for imprecision of effect estimates ᶜDowngraded for heterogeneity among included studies Discussion The current meta-analysis demonstrated that benralizumab significantly improves lung function and asthma control compared with placebo [22, 35]. Specifically, treatment with benralizumab resulted in a statistically significant increase in forced expiratory volume in 1 s (FEV₁) and a significant reduction in Asthma Control Questionnaire (ACQ) scores. Importantly, the safety profile of benralizumab was comparable to placebo, with no significant difference in adverse events. Contrary to the initial assertion in the draft, our pooled analysis also revealed a statistically significant reduction in exacerbation rates with benralizumab versus control. These findings support the efficacy and safety of benralizumab in severe eosinophilic asthma. However, the substantial heterogeneity observed across key outcomes underscores that these benefits are not uniform; the pooled estimates reflect average effects across diverse populations, and individual responses may differ based on clinical and biological characteristics [18, 19]. The observed improvement in FEV₁ aligns with the known mechanism of benralizumab, a cytolytic anti–IL-5 receptor α monoclonal antibody that induces rapid and near-complete depletion of eosinophils [20, 21]. Eosinophilic inflammation is a key driver of airway obstruction and hyper-responsiveness in this phenotype [5–7]. The pooled mean difference of 0.107 L, is clinically meaningful in a severe population where incremental gains in lung function are valuable. However, substantial heterogeneity (I2 = 71.2%) was observed across the FEV₁ analyses, likely reflecting variations in study designs, patient populations (e.g., differences in baseline eosinophil thresholds, prior biologic use, and degree of airway remodeling), treatment durations, and background therapy. This heterogeneity underscores the importance of patient selection and suggests that the magnitude of lung function response may vary across clinical subgroups [24, 26]. The study noted that the magnitude of FEV₁ improvement observed with benralizumab (≈ 0.11 L) is comparable to that reported in meta-analyses of other anti-IL-5 agents like mepolizumab and reslizumab in similar patient populations [28]. While this represents a reasonable absolute gain, in a severe asthma population with significant baseline airflow limitation (often with an FEV₁ < 60% predicted), even such an improvement can translate to reduced hyperinflation and improved quality of life for some patients. Conversely, the mean ACQ improvement of − 0.17 points, while statistically significant, does not reach the 0.5-point threshold widely accepted as the minimal clinically important difference [47, 48]. This highlights a crucial distinction between statistical efficacy and the patient’s subjective perception of improvement, underscoring that the most profound and consistent benefit of benralizumab in this analysis is the prevention of exacerbations rather than a large average improvement in daily symptoms. Regarding asthma control, the significant reduction in ACQ score (MD = − 0.21) confirms that benralizumab leads to a statistically significant, though on average, improvement in patient-reported symptom scores [43]. The pooled MD falls below the MCID of − 0.5 for the ACQ, showing that while the treatment effect is real at the group level, the average magnitude may not be subjectively noticeable for all individuals [47, 48]. However, a significant proportion of patients in phase III trials do achieve clinically meaningful responses. The heterogeneous treatment effects highlight the need for predictive biomarkers to identify those most likely to experience substantial symptomatic benefit [26, 49]. A key finding of our analysis is the significant reduction in exacerbation rates associated with benralizumab which aligns with the primary outcomes of major phase III trials (SIROCCO, CALIMA, ZONDA) and strengthens the drug’s efficacy in preventing severe asthma events, which is observed as a critical goal in managing this high-risk population [22, 23, 35]. The effect on exacerbations is a cornerstone of benralizumab’s value, as it directly reduces disease morbidity, healthcare utilization, and the associated burden of systemic corticosteroid exposure [8–10, 13–17]. The rate of adverse events between the benralizumab and placebo groups reinforces its favorable safety profile, as established in clinical development programs [27, 44]. When positioning benralizumab among other biologics targeting the IL-5 pathway (mepolizumab, reslizumab), our analysis supports its distinct pharmacodynamics profile. By directly targeting the IL-5 receptor and inducing antibody-dependent cellular cytotoxicity (ADCC), benralizumab achieves a more profound and rapid eosinophil depletion [20]. This mechanism may translate into specific efficacy advantages, particularly in patients with high eosinophil burdens [50]. However, cross-trial comparisons are inherently limited. Head-to-head studies are needed to definitively establish comparative effectiveness on specific endpoints like lung function improvement, exacerbation reduction in well-matched subgroups, and speed of onset [18, 19, 51–58]. The inclusion of adolescent patients (≥ 12 years) in some analyzed studies, such as Busse et al. (2021), is justified by the shared IL-5-driven pathophysiology of severe eosinophilic asthma across age groups [46]. The consistent efficacy and safety signals in this subgroup support the extrapolation of benefits to the adolescent population, in line with its approved indication. However, it is important to acknowledge that this evidence base is limited. Only one small trial [46] specifically enrolled adolescents, contributing 61 participants to the pooled analysis of 5,502 patients. Consequently, the pooled effect estimates presented in this meta-analysis are overwhelmingly driven by adult data. While the mechanistic rationale for efficacy in adolescents is sound, caution should be exercised when generalizing these findings to broader pediatric populations, particularly younger children (< 12 years), who were not represented in any of the included trials. Future research should prioritize pediatric-specific meta-analyses or, ideally, individual patient data (IPD) analyses to confirm efficacy and safety in this younger age group and to explore potential age-related differences in treatment response. Study limitations and strengths Although this meta-analysis provides valuable insights and findings, limitations should also be acknowledged. The follow-up durations differed among studies, which can affect the assessment of long-term outcomes. Moreover, our analysis could not perform extensive subgroup analyses (e.g., by baseline eosinophil level, OCS dependence, or presence of nasal polyps) due to inconsistent reporting in the original studies. However, the strengths of this work include adherence to PRISMA guidelines, rigorous risk-of-bias assessment using RoB 2.0, and the application of appropriate random-effects models to account for heterogeneity. Additionally, this analysis did not evaluate oral corticosteroid (OCS) dose reduction or asthma-specific quality of life (AQLQ), which are important outcomes in severe asthma management. This decision was intentional, as these endpoints were not uniformly reported across the included trials; OCS-sparing effects, for instance, were primarily assessed in dedicated trials (e.g., ZONDA, SHAMAL) involving OCS-dependent populations. Although substantial heterogeneity was present for several outcomes, the sensitivity analyses confirmed that no individual study disproportionately influenced the pooled estimates. It is important to acknowledge that Egger’s test has limited statistical power in meta-analyses with fewer studies; therefore, non-significant results (p > 0.05) should not be interpreted as evidence of the absence of publication bias. Conclusion and future directions In conclusion, this meta-analysis provides robust evidence that benralizumab is an effective therapy for severe eosinophilic asthma. While it provides statistically significant improvements in lung function (averaging 0.11 L) and asthma control (below the minimal clinically important difference), its most clinically meaningful impact is the significant reduction in exacerbation rates. Importantly, the high heterogeneity observed across studies (I2 ≈ 70% for several outcomes) indicates that these are average effects; individual patient responses may vary considerably. These findings underscore three research priorities. First, individual patient data meta-analyses are needed to identify predictors of superlative response (e.g., baseline eosinophil thresholds, comorbidities). Second, head-to-head trials comparing benralizumab directly with mepolizumab and reslizumab are required to establish comparative effectiveness. Third, long-term real-world studies should evaluate steroid-sparing effects, rare adverse events, and effectiveness in underrepresented populations (adolescents, the elderly).